Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350


Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.

Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D.

Cancer Res. 2007 Apr 15;67(8):3708-15.


High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.

Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D.

Cancer Res. 2010 Jul 1;70(13):5399-408. doi: 10.1158/0008-5472.CAN-10-0090. Epub 2010 Jun 8.


Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.

Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M.

Int J Oncol. 2006 Jan;28(1):127-33.


Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.

Castro-Gamero AM, Borges KS, da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, Scrideli CA, Umezawa K, Tone LG.

Anticancer Drugs. 2012 Jul;23(6):638-50. doi: 10.1097/CAD.0b013e328350e835.


Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.

Fromigué O, Hamidouche Z, Marie PJ.

J Pharmacol Exp Ther. 2008 May;325(2):595-600. doi: 10.1124/jpet.108.136127. Epub 2008 Feb 5.


E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.

Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, Banerjee D, Bertino JR.

Cancer Res. 2006 Jul 15;66(14):7253-60.


Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.

Marion A, Dieudonné FX, Patiño-Garcia A, Lecanda F, Marie PJ, Modrowski D.

Int J Cancer. 2012 Jun 1;130(11):2514-25. doi: 10.1002/ijc.26246. Epub 2011 Aug 16.


Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.

Zou J, Gan M, Mao N, Zhu X, Shi Q, Yang H.

Arch Med Res. 2010 Apr;41(3):162-9. doi: 10.1016/j.arcmed.2010.04.006.


Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.

Dieudonné FX, Marion A, Marie PJ, Modrowski D.

J Bone Miner Res. 2012 Oct;27(10):2118-29. doi: 10.1002/jbmr.1650.


Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Patiño-García A, Zalacain M, Folio C, Zandueta C, Sierrasesúmaga L, San Julián M, Toledo G, De Las Rivas J, Lecanda F.

Clin Cancer Res. 2009 Aug 15;15(16):5082-91. doi: 10.1158/1078-0432.CCR-09-0300. Epub 2009 Aug 11.


Dual involvement of protein kinase C delta in apoptosis induced by syndecan-2 in osteoblasts.

Orosco A, Fromigué O, Haÿ E, Marie PJ, Modrowski D.

J Cell Biochem. 2006 Jul 1;98(4):838-50.


p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.

Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT.

Mol Cancer Ther. 2007 Mar;6(3):1054-61.


Dexamethasone protects against Cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells.

Meyer S, Eden T, Kalirai H.

Cancer Biol Ther. 2006 Aug;5(8):915-20. Epub 2006 Aug 2.


Syndecan-2 overexpression induces osteosarcoma cell apoptosis: Implication of syndecan-2 cytoplasmic domain and JNK signaling.

Modrowski D, Orosco A, Thévenard J, Fromigué O, Marie PJ.

Bone. 2005 Aug;37(2):180-9.


Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.

Bruheim S, Xi Y, Ju J, Fodstad O.

Clin Cancer Res. 2009 Dec 1;15(23):7161-9. doi: 10.1158/1078-0432.CCR-08-2816. Epub 2009 Nov 17.


Apoptotic effects of curcumin on human osteosarcoma U2OS cells.

Jin S, Xu HG, Shen JN, Chen XW, Wang H, Zhou JG.

Orthop Surg. 2009 May;1(2):144-52. doi: 10.1111/j.1757-7861.2009.00019.x.


Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.

Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, Komiya S.

Anticancer Res. 2008 Jul-Aug;28(4B):2147-54.

Supplemental Content

Support Center